Users of TAF in PrEP more likely to develop high blood pressure or need statins

By | 15th September 2023

“A study of people who started PrEP in a southern California health system has found that people who took PrEP containing tenofovir alafenamide (TAF) were more likely to be diagnosed with high blood pressure or start treatment with a statin to control cholesterol than those taking PrEP containing tenofovir disoproxil (TDF) during a two-year follow-up.” Reports NAM aidsmap.

The combination of tenofovir alafenamide and emtricitabine – known as “Descovy” – is widely prescribed in the United States. It does not have a license in the EU, but has been approved for use in the four nations of the UK, where so far it has been given to a very small number of PrEP users.

Leave a Reply

Your email address will not be published. Required fields are marked *


− 2 = five